Bayer Doubles OTC Presence In China With Dihon Acquisition
This article was originally published in PharmAsia News
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
You may also be interested in...
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?